Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
25.34
-1.09 (-4.12%)
May 15, 2026, 11:26 AM EDT - Market open

Maze Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22
1,4022,044---
Market Cap Growth
246.19%----
Enterprise Value
1,1721,721000
Last Close Price
25.3441.43---
PE Ratio
--13.58---
PB Ratio
3.825.76---
P/TBV Ratio
3.655.02---
P/FCF Ratio
--18.13---
P/OCF Ratio
--18.26---
EV/EBITDA Ratio
--12.25---
EV/EBIT Ratio
--12.04---
EV/FCF Ratio
--15.26---
Debt / Equity Ratio
0.170.05-0.07-0.12-0.10
Debt / EBITDA Ratio
-0.46-0.170.44-0.52-0.30
Debt / FCF Ratio
-0.50-0.210.36-0.57-0.32
Net Debt / Equity Ratio
-0.85-0.900.55-0.050.24
Net Debt / EBITDA Ratio
2.212.27-2.79-0.220.63
Net Debt / FCF Ratio
2.392.83-2.27-0.230.67
Asset Turnover
0.0501.0700
Quick Ratio
17.5415.169.521.794.81
Current Ratio
17.8815.509.762.095.11
Return on Equity (ROE)
-35.18%-598.95%-15.25%30.60%40.69%
Return on Assets (ROA)
-32.82%-44.82%36.10%-89.00%-74.04%
Return on Invested Capital (ROIC)
-303.36%-438.76%193.52%-307.50%-330.64%
Return on Capital Employed (ROCE)
-34.68%-48.08%41.87%-106.91%-85.95%
Earnings Yield
-8.38%-7.36%---
FCF Yield
-8.35%-5.52%---
Buyback Yield / Dilution
-449.59%-1474.04%-19.33%-13.88%-
Total Shareholder Return
-449.59%-1474.04%-19.33%-13.88%-
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q